-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $997

Benzinga·11/02/2026 19:58:21
語音播報
Leerink Partners analyst David Risinger maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Market Perform and raises the price target from $835 to $997.